Navigation Links
Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
Date:11/23/2009

CARLSBAD, Calif., Nov. 23 /PRNewswire-FirstCall/ --

Dear Isis Supporters and Shareholders,

I would like to start by thanking you for your continuing support of Isis. We believe we are at one of the most successful moments in our history. We are truly at the end of the beginning of creating a unique company with a novel drug discovery platform, which we believe addresses many of the issues haunting the pharmaceutical industry.

Our progress is predicated largely upon the success of our flagship drug, mipomersen. Mipomersen continues to perform well and progress toward commercialization. Isis, our investigators and members of the medical community are very encouraged by the results that were presented at the AHA last week. To get a sense of their support of the drug, I would encourage you to listen to the replay of the mipomersen investigator panel presentation that was conducted during AHA last week. I think you will hear not only their enthusiasm for the drug but their hope that mipomersen will provide a new treatment alternative for their patients at very high risk of cardiovascular disease.

We are disappointed with the reaction on Wall Street to what we believe is very positive news. We believe mipomersen will continue to provide results that speak for themselves. Each success brings us closer to getting mipomersen to the market and making the drug available to patients in need.

Our antisense technology provides a direct route from genes to drugs with the opportunity to dramatically improve the productivity of the pharmaceutical industry. With 19 drugs in development, we have one of the largest and most diverse pipelines in our industry. We know that sick people depend on us. We continue to strive for excellence as we create drugs for the future. We also recognize that behind our successes is the support we receive from you. I would like to personally thank you for that.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
2. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
3. Cadence Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Quarter 2008
5. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
6. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
7. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
8. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
9. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
10. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
11. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... sisters in high school have developed ways to measure ... use electronic stethoscopes, which electronically amplify body sounds, to ... heartbeats. Ilina, a senior at Port Huron Northern ... to detect early lung damage in people exposed to ... one breath cycle each from 16 smokers, 25 nonsmokers ...
(Date:10/22/2014)... (HealthDay News) -- Measures taken by Firestone officials at ... may have limited the spread of the disease there ... Firestone Natural Rubber Co. provides health services to about ... densely populated communities. Between Aug. 1 and Sept. ... among those 80,000 people. That incidence rate of 0.09 ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market ... of facts, figures and forecasts on the global medical ... forecast categories the Worldwide Medical Market Forecasts to ... views on the worldwide medical market to reveal key ... you data for 2010-2019, covering each country market individually, ...
(Date:10/20/2014)... The Advocator Group, LLC ... American Foundation for Suicide Prevention’s (AFSP) Out of the ... not-for-profit organization that hosts hundreds of community walks throughout ... are used to help understand and prevent suicide through ... as well. , The Advocator Group shares this ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... , , TOMBALL, Texas, ... that created relaxation category brand leader Purple Stuff; has released ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20090914/DA75426 ) , , ... drink that combines energy, appetite control, calorie burners and 100% ...
... , ATLANTA, Sept. 15 As ... words." This month HIPAA.com launches its sister site, HIPAA TV, ... do and how to go about it. HIPAA TV expands ... demonstrations, case studies, and satire as they relate to HIPAA, ...
... , , ... people with disabilities and gain valuable advocacy tools at one of ... with Disabilities (MN-CCD). Learn how the 2009 legislative session impacts ... person-centered programs; and speak directly to legislators about your challenges and ...
... , , HARTFORD, Conn., Sept. ... health insurance these days than ever. But, when it comes to ... take advantage of their options when choosing benefits during Open Enrollment ... from Plan for Your Health , the health benefits public ...
... , , , ... the world,s leading research and advisory firms for pharmaceutical and ... Spain and U.K.) sales of Roche/Biogen Idec,s Rituxan/MabThera, Bristol-Myers Squibb/Merck,s ... in 2014, before falling to roughly $10 billion in 2018. ...
... treatments for bronchitis, asthma, researchers say , TUESDAY, ... genetic switch that makes mucus production go into overdrive ... ailments, a new study says. , Excessive mucus ... from asthma, cystic fibrosis, bronchitis, common colds and other ...
Cached Medicine News:Health News:Funktional Beverages, Inc. Creates the Ultimate Weight Management Sports Drink. 2Health News:Funktional Beverages, Inc. Creates the Ultimate Weight Management Sports Drink. 3Health News:HIPAA.com Launches HIPAA TV 2Health News:Disability Matters: Learn Your Rights, Preserve Your Independence 2Health News:Consumers Overlooking Opportunities at Open Enrollment May be Missing Out 2Health News:Consumers Overlooking Opportunities at Open Enrollment May be Missing Out 3Health News:Consumers Overlooking Opportunities at Open Enrollment May be Missing Out 4Health News:Consumers Overlooking Opportunities at Open Enrollment May be Missing Out 5Health News:Consumers Overlooking Opportunities at Open Enrollment May be Missing Out 6Health News:Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018 2Health News:Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018 3
(Date:10/22/2014)... 2014 Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes ... investigational drug for cancer, is designed for injection into ... Its oncology focus is on melanoma, breast cancer and ... trials of PV-10 as a therapy for metastatic melanoma, ... dermatitis and psoriasis. This summer, the ...
(Date:10/22/2014)... and SHANGHAI , Oct. 22, 2014 ... FMI ) and WuXi PharmaTech (Cayman) Inc. (NYSE: ... offer Foundation Medicine,s comprehensive genomic profiling to biopharmaceutical companies ... Under the terms of the collaboration, ... the laboratory component of Foundation Medicine,s FoundationOne® assay at ...
(Date:10/20/2014)... , Oct. 20, 2014  Luoxis Diagnostics, Inc., ... AMPE), today announced that its academic collaborators will ... research potential for its novel RedoxSYS Diagnostic System, ... in the body in response to injury or ... ORP as a clinical marker will be presented ...
Breaking Medicine Technology:Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
... June 20 Advocate Christ,Medical Center in Oak Lawn, ... the Chicago area, the only one in the Advocate ... are using a glue-like liquid for,the successful treatment of ... procedure, Thomas J. Grobelny MD, of,the medical center,s Neurosciences ...
... SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; ... the U.S. Food,and Drug Administration (FDA) have reached ... for bronchiectasis via the Special,Protocol Assessment process., ... a clinical trial protocol,intended to form the primary ...
Cached Medicine Technology:Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3
Provides 30% more magnification and twice the field of view. Adjustable focus, with insufflator bulb....
Features a built-in throat illuminator, providing 30% more magnification and twice the field of view. Adjustable focus....
... Novus Spectra photocoagulator delivers power and ... solid-state (DPSS) technology. Diode side-pumping technology ... the compact Novus Spectra system, and ... beam output and system reliability from ...
A standard, durable and reliable indirect....
Medicine Products: